Evidence map›Paper›PMID 29228732›Full record

ArticleOncotarget2017

Vijay Negi, Bandana A Vishwakarma, Su Chu, Kevin Oakley, Yufen Han, Ravi Bhatia, Yang Du

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Targeting the N-cadherin/Frontiers in oncology · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vijay NegiDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Bandana A VishwakarmaDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Su ChuDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Kevin OakleyDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Yufen HanDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Ravi BhatiaDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Yang DuDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Uniformed Services University of the Health Sciences · USUniversity of Alabama at Birmingham · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Resistance of CML stem cells to STI571 (Gleevec)R01CA095684 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, RAVI · 2003 to 2017
$4.6M
NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA095684
6 · The paper itself

Abstract

Mechanisms underlying the progression of Chronic Myeloid Leukemia (CML) from chronic phase to myeloid blast crisis are poorly understood. Our previous studies have suggested that overexpression of

Indexed as

blast crisischronic myeloid leukemiaHoxa10Hoxa9Myb

Identifiers

PMID29228732
PMCPMC5716772
OpenAlexW2765410107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.